(CercleFinance.com) – Carmat announces that it has reached the milestone of 50 implantations of its total artificial heart and takes stock of its achievements and prospects. 41 hospitals in 12 countries are trained in implementations, including 33 for commercial activity.
The company achieved a turnover of 2.8 ME in 2023, marked by a clear acceleration in sales in the fourth quarter with 11 establishments out of the 17 carried out during the year. It is targeting a turnover of 14 to 20 ME.
Carmat will launch a capital increase in the very short term to extend the financial horizon beyond the end of January 2024 and partially finance the Company’s needs over 12 months, estimated at a minimum of €50 million.
Stéphane Piat, Managing Director of Carmat, declares: ‘This milestone constitutes an important success and also demonstrates recognition of our therapy by big names in cardiology’.
‘All of these advances constitute a solid foundation for a large-scale commercial deployment, allowing Carmat to achieve its ultimate objective of providing patients waiting for a human heart with a therapeutic solution and comfort of life. We approach 2024 with confidence and great determination to achieve the objectives we have set for ourselves. ‘